Cytiva News

  1. GE Healthcare Life Sciences Allies With Pharmadule Morimatsu To Expand KUBio 12/5/2019

    The KUBio “factory in a box” is expanding to accelerate the accessibility of biotherapeutics on a global scale. Additional modular platforms will be introduced in 2020 allowing biopharma manufacturers to quickly scale up vaccines, viral vector-based therapies, and other novel modalities.

  2. New KUBio Box For Viral Vectors Boosts Gene Therapy Manufacturing 10/28/2019

    GE Healthcare Life Sciences is launching KUBio™ box, a fully-integrated, flexible, and adaptable biomanufacturing environment to accelerate the production of viral vector-based gene therapies. The latest addition to the KUBio modular bioprocessing portfolio, KUBio box is expected to speed gene therapies to market and contribute to increased capacity in the viral vector area.

  3. Avalon GloboCare, GE Healthcare To Accelerate Bioproduction Of Cellular Medicines 7/24/2019

    Avalon GloboCare Corp., a leading clinical-stage global developer of cell-based technologies and therapeutics, has announced that they have established a strategic partnership with GE Healthcare.

  4. GE Healthcare And World Courier Collaborate To Drive Commercialization Of Cell And Gene Therapies 5/28/2019

    GE Healthcare and World Courier, a part of AmerisourceBergen, are combining their expertise in manufacturing and logistics to better patient access to cell and gene therapies. Together, they aim to create a seamless end-to-end supply chain that will enable the developers of these treatments to meet increasing global demand.

  5. Cobra Biologics, GE Healthcare And Centre For Process Innovation Collaborate To Advance Gene Therapy 9/25/2018

    Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) of biologics and pharmaceuticals, announced a collaboration with the Centre for Process Innovation (CPI), a UK-based technology innovation centre and GE Healthcare Life Sciences. The three-way partnership, funded by a £570K Innovate UK grant, aims to increase the robustness and reduce costs for the manufacturing of adeno-associated virus (AAV) vectors, a delivery vehicle used for emerging gene therapy treatments. The gene therapy area has been developing rapidly and while only a small number of treatments are already approved for use, more than 200 clinical trials are underway.